Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253635 | 0.79 | HSD17B10 (0.41) | IMPDH2ALDH1A1HSD17B10HPGDTSHR | |
| SCHEMBL8579502 | 0.79 | ALDH1A1 (0.46) | IMPDH2ALDH1A1HSD17B10HPGDTSHR | |
| SCHEMBL9294181 | 0.78 | HSD17B10 (0.57) | ALDH1A1HSD17B10HPGDTSHRCYP3A4 | |
| SCHEMBL29625674 | 0.78 | HSD17B10 (0.57) | ALDH1A1HSD17B10HPGDTSHRCYP3A4 | |
| SCHEMBL8637918 | 0.78 | HSD17B10 (0.40) | IMPDH2ALDH1A1HSD17B10HPGDTSHR | |
| SCHEMBL301407 | 0.78 | HSD17B10 (0.40) | IMPDH2ALDH1A1HSD17B10HPGDTSHR | |
| SCHEMBL1325658 | 0.78 | HSD17B10 (0.63) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| SCHEMBL7198503 | 0.78 | TSHR (0.48) | IMPDH2ALDH1A1HSD17B10HPGDTSHR | |
| SCHEMBL2533977 | 0.78 | HSD17B10 (0.40) | IMPDH2ALDH1A1HSD17B10HPGDTSHR | |
| SCHEMBL31201820 | 0.78 | HSD17B10 (0.63) | ALDH1A1HSD17B10HPGDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4131587-A | ORGANIC AMINES | EXXON RESEARCH & ENGINEERING CO. (US) | 1978-12-26 | — | — | US | claimed |
| EP-3184171-B1 | PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS | CHEVRON PHILLIPS CHEMICAL CO LP (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10144752-B2 | Phosphinyl amidine compounds, metal complexes, catalyst systems, and their use to oligomerize or polymerize olefins | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2018-12-04 | — | — | US | disclosed |
| US-9962689-B2 | Phosphinyl formamidine compounds, metal complexes, catalyst systems, and their use to oligomerize or polymerize olefins | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170305945-A1 | Phosphinyl Amidine Compounds, Metal Complexes, Catalyst Systems, and Their Use to Oligomerize or Polymerize Olefins | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2017-10-26 | — | — | US | disclosed |
| US-9732106-B2 | Phosphinyl amidine compounds, metal complexes, catalyst systems, and their use to oligomerize or polymerize olefins | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3184171-A1 | PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS | Chevron Phillips Chemical Company LP (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2519532-B1 | PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS | CHEVRON PHILLIPS CHEMICAL CO LP (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160375431-A1 | Phosphinyl Formamidine Compounds, Metal Complexes, Catalyst Systems, and Their Use to Oligomerize or Polymerize Olefins | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2016-12-29 | — | — | US | disclosed |
| EP-3083646-A1 | PHOSPHINYL FORMAMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS | Chevron Phillips Chemical Company LP (US) | 2016-10-26 | — | — | EP | disclosed |
| US-5661185-A | AN ALKOXYPHENYL-ALKYLUREA COMPOUND TREATING SLEEP DISORDER | BRISTOL-MYERS SQUIBB CO. (US) | 1997-08-26 | — | — | US | disclosed |
| US-5661186-A | MELATONERGIC EFFECT; CENTRAL NERVOUS SYSTEM DISODERS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0728738-A1 | Tetralinyl- and indanyl-ethylamides having melatonergic activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-28 | — | — | EP | disclosed |
| US-5541228-A | Melatonergic agents | BRISTOL-MYERS SQUIBB CO. (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0718286-A1 | 3-Alkoxybenzylpiperidine derivatives as melatonergic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-06-26 | — | — | EP | disclosed |
| US-5530012-A | FOR SLEEP DISORDERS, DEPRESSION, GLAUCOMA, CANCER | BRISTOL-MYERS SQUIBB CO. (US) | 1996-06-25 | — | — | US | disclosed |
| EP-0706994-A1 | Melatonergic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-17 | — | — | EP | disclosed |
| US-5318994-A | Treating melatoninergic disorders | ADIR ET COMPAGNIE (FR) | 1994-06-07 | — | — | US | disclosed |
| US-5225442-A | Melatoninergic disorders | ADIR ET COMPAGNIE (FR) | 1993-07-06 | — | — | US | disclosed |
| US-5194614-A | COMPOUNDS HAVING A NAPHTHALENE STRUCTURE | ADIR ET COMPAGNIE (FR) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144752-B2 | Phosphinyl amidine compounds, metal complexes, catalyst systems, and their use to oligomerize or polymerize olefins | NIT2, NCLN, NPM1 | IMPDH2 1314/4885ALDH1A1 4849/4885HSD17B10 4182/4885 |
| US-20170305945-A1 | Phosphinyl Amidine Compounds, Metal Complexes, Catalyst Systems, and Their Use to Oligomerize or Polymerize Olefins | NIT2, NCLN, NPM1 | IMPDH2 1314/4885ALDH1A1 4849/4885HSD17B10 4182/4885 |
| US-20160375431-A1 | Phosphinyl Formamidine Compounds, Metal Complexes, Catalyst Systems, and Their Use to Oligomerize or Polymerize Olefins | NIT2, INF2, PFAS | IMPDH2 990/4885ALDH1A1 4794/4885HSD17B10 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.